Trevena Stock Price, News & Analysis

Trevena, Inc. (TRVN) is a biopharmaceutical company focused on the development and commercialization of medicines for patients with central nervous system (CNS) disorders. According to company disclosures, Trevena concentrates on both an approved hospital-based pain therapy and a pipeline of investigational CNS drug candidates. The company is classified under pharmaceutical preparation manufacturing within the broader manufacturing sector.

Trevena’s business centers on two main areas: its approved product OLINVYK and a pipeline of CNS-focused investigational medicines. The company states that its pipeline is based on Nobel Prize winning research and includes differentiated drug candidates targeting pain, epilepsy, migraine and opioid use disorder.

Approved Product: OLINVYK Injection

The company reports that it has one approved product in the United States, OLINVYK (oliceridine) injection. OLINVYK is described as a new chemical entity approved by the U.S. Food and Drug Administration in August 2020. It contains oliceridine, an opioid and Schedule II controlled substance. OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.

Company materials explain that OLINVYK is available in single-dose vials and a single-patient-use vial for patient-controlled analgesia (PCA). Approved PCA doses and a maximum cumulative daily dose are specified in the prescribing information. The labeling and safety information emphasize risks typical of opioids, including addiction, abuse, misuse, serious or life-threatening respiratory depression, risks when combined with benzodiazepines or other CNS depressants, neonatal opioid withdrawal syndrome, and other opioid-related warnings and precautions. Trevena notes that OLINVYK remains available for purchase and that the company continues to comply with regulatory requirements, including post-marketing surveillance and reporting obligations.

Pipeline of CNS Investigational Candidates

Trevena describes a pipeline of three investigational drug candidates:

• TRV045 – a novel, highly selective sphingosine-1-phosphate subtype 1 (S1P1) receptor modulator being developed as a potential treatment for acute and chronic neuropathic pain secondary to diabetic peripheral neuropathy. Through a collaboration with the National Institutes of Health (NIH), Trevena is also exploring TRV045 as a potential treatment for epilepsy. The company reports that TRV045 has shown analgesic-like effects in nonclinical models of neuropathic pain, with reversal of thermal hyperalgesia in models of diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy. In nonclinical studies, TRV045 was not associated with lymphopenia and produced no changes in blood pressure, heart rate or respiratory function at or above pharmacologically active doses.
• TRV250 – identified by Trevena as an investigational candidate for the acute treatment of migraine.
• TRV734 – identified as an investigational candidate for maintenance treatment of opioid use disorder.

The company states that TRV045 has been evaluated in multiple Phase 1 studies and proof-of-concept studies, where it demonstrated a favorable tolerability profile and evidence of CNS target engagement in models of neuropathic pain and epilepsy-related measures. Trevena also reports ongoing formulation optimization and toxicology work intended to support later-stage clinical development.

Focus on CNS Disorders and Research Collaborations

Across its programs, Trevena positions itself as a CNS-focused biopharmaceutical developer. It highlights collaborations with academic and government partners, including scientists at Virginia Commonwealth University and the NIH-supported Epilepsy Therapy Screening Program (ETSP), to study TRV045 in preclinical models of neuropathic pain and epilepsy. Company communications describe TRV045 as having shown anti-seizure effects in validated animal models and providing additional mechanistic insight into S1P1 receptor signaling in pain pathways.

Strategic Review and Corporate Actions

Trevena has disclosed a series of corporate and capital structure actions. The company reports that it has undertaken a strategic review of alternatives for OLINVYK and for its pipeline assets, including potential sale, license, divestiture, discontinuation of U.S. commercial sales of OLINVYK, or a sale, merger or wind down of the company. Trevena notes that there can be no assurance that any particular transaction will be pursued or completed.

The company also reports cost-cutting measures, including reductions in commercial support for OLINVYK and workforce reductions, as well as changes in senior executive employment arrangements and board composition. These steps are described as efforts to find operational efficiencies and preserve capital while focusing resources on TRV045 and other priorities.

Trading Status and Capital Markets Activity

Trevena’s common stock historically traded on the Nasdaq Capital Market under the symbol TRVN. Company announcements state that in August 2024 Trevena effected a 1-for-25 reverse stock split of its common stock, intended to help regain compliance with Nasdaq’s minimum bid price requirement. Subsequently, Trevena disclosed that the Nasdaq Hearings Panel determined to delist the company’s common stock due to non-compliance with Nasdaq’s minimum stockholder’s equity requirement. Trading in the company’s common stock was suspended on Nasdaq effective with the open of business on October 8, 2024.

Trevena reported that its common stock began trading on the Pink Open Market operated by OTC Markets Group on October 8, 2024 under the symbol TRVN. A later SEC filing identifies the trading venue as the OTC Expert Market. The company has also described various financing transactions, including private placements and warrant exercises, as well as royalty-based financing arrangements related to OLINVYK, some of which have been amended to adjust terms and reduce outstanding liabilities.

Royalty Financing and Assignment Agreement

In an SEC Form 8-K, Trevena reports that on January 9, 2026, Trevena, Inc. and certain affiliated entities entered into an Assignment and Release Agreement with Jiangsu Nhwa Pharmaceutical Co. Ltd. and an R-Bridge-affiliated lender. Under this agreement, the lender agreed to terminate and release the company from obligations under a royalty-based loan agreement entered into in March 2022 and amended in July 2024, other than indemnification and other surviving obligations. In exchange, Trevena agreed to transfer all rights, title and interest under its Chinese License Agreement with Jiangsu Nhwa for royalties in the China territory, other than rights to commercialization milestone payments.

Headquarters and Corporate Classification

According to SEC filings, Trevena, Inc. is incorporated in Delaware. A recent filing lists the company’s principal executive offices in Atlanta, Georgia. The company’s securities are registered under Section 12 of the Securities Exchange Act, and its common stock, with a par value of $0.001 per share, is listed as trading under the symbol TRVN on an OTC market.

Position Within the Biopharmaceutical Sector

Within pharmaceutical preparation manufacturing, Trevena represents a CNS-focused biopharmaceutical issuer with a mix of commercial-stage and development-stage assets. Its disclosures emphasize OLINVYK as an FDA-approved opioid analgesic for acute pain in adults requiring intravenous opioid therapy when alternatives are inadequate, and a pipeline of investigational candidates targeting neuropathic pain, epilepsy, migraine and opioid use disorder. The company’s recent communications highlight ongoing strategic review, cost management, and a shift in trading venue from a national securities exchange to the OTC markets.